Serum HER2 levels predict treatment efficacy and prognosis in patients with HER2-positive breast cancer undergoing neoadjuvant treatment | Zendy

WenJia Zuo | Zendy; Min He | Zendy; Hui Zheng | Zendy; Yin Liu | Zendy; Xiyu Liu | Zendy; YiZhou Jiang | Zendy; Zhonghua Wang | Zendy; Renquan Lu | Zendy; ZhiMing Shao | Zendy

Open Access

Serum HER2 levels predict treatment efficacy and prognosis in patients with HER2-positive breast cancer undergoing neoadjuvant treatment

Author(s) -

WenJia Zuo,

Min He,

Hui Zheng,

Yin Liu,

Xiyu Liu,

YiZhou Jiang,

Zhonghua Wang,

Renquan Lu,

ZhiMing Shao

Publication year - 2021

Publication title -

gland surgery

Language(s) - English

Resource type - Journals

eISSN - 2227-8575

pISSN - 2227-684X

DOI - 10.21037/gs-20-802

Subject(s) - medicine , breast cancer , oncology , trastuzumab , stage (stratigraphy) , chemotherapy , cancer , human epidermal growth factor receptor 2 , pathological , hazard ratio , confidence interval , paleontology , biology

Controversy remains regarding the predictive and prognostic value of serum human epidermal growth factor receptor 2 (HER2) in breast cancer. The purpose of this retrospective study was to determine the clinical utility and efficacy of serum HER2 (sHER2) in predicting treatment response and prognosis in patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy and trastuzumab treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research